Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of pharmaceutical products for the treatment of human diseases, including those in the fields of immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211, which has completed Phase II clinical trials for the treatment of type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032, which has completed Phase II clinical trials for the treatment of symptoms associated with carcinoid syndrome. Additionally, the company is developing a preclinical drug candidate, LX7101, for the treatment of glaucoma. Lexicon Pharmaceuticals has established drug discovery alliances with Bristol-Myers Squibb Company, Genentech, Inc., N.V. Organon, and Takeda Pharmaceutical Company Limited. It also has a drug development financing collaboration with Symphony Icon, a collaboration agreement with Taconic Farms, Inc., and an alliance with Nuevolution A/S for access to Nuevolution's Chemetics platform chemistry technology.